Pharmaxis shares dive 30% on trial results
Pharmaceutical company, Pharmaxis (ASX:PXS) underwhelmed the market with the results from their phase III clinical trial of cystic fibrosis treatment drug Bronchitol®.
- Week in security: Are cybercriminals getting ready to storm the BlueKeep?
- GitHub token scanning comes to Alibaba, AWS, Azure, Google and more
- Google Chrome password study: 25% users ignored a breached password alert
- ASD tells Australia how to adopt DMARC to fight email spoofing attacks
- BlueKeep-like wormable flaws hit Windows 10: Microsoft urges immediate patch